-
Mashup Score: 0Use of the National Cancer Institute Community Cancer Centers Program Screening and Accrual Log to Address Cancer Clinical Trial Accrual - 1 hour(s) ago
Use of screening logs to document enrollment barriers at the local level can facilitate development of strategies to enhance accrual.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Posters - ESMO Congress 2023 - 2 day(s) ago
Marwan Fakih (Duarte, United States of America) We have previously reported significant differences between the tumor immune microenvironm ent (TIME) of primary colorectal cancer (CRC-P) and different metastatic sites. Increased immune cell infiltration, B-cells, and CD8 cells and decreased macrophages were noted in CRC-P and lung metastatic (LuM) lesions compared to liver (LM) and peritoneum (PM) metastases. We expanded our work to MSI CRC and compared their TIME to respective MSS tumor sites. De-identifi
Source: cslide.ctimeetingtech.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy - 2 day(s) ago
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines - 2 day(s) ago
This cross-sectional study examines the prevalence of germline findings in patients undergoing tumor/normal matched sequencing among cancer types lacking guidelines.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 day(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database, we examined whether dual tissue and ctDNA testing, “dual testing”, improved identification of actionable variants compared with either modality alone. Methods: We used Tempus Lens to retrospectively analyze 3153 de-identified stage 4 patients (breast [N = 644], colorectal [N = 841], non-small cell lung cancer (NSCLC) [N = 1232], and prostate [N = 436]). Each patient had dual testing—Tempus xF (ctDNA, 105 panel genes) and Tempus xT (tumor tissue, 595-648 panel genes), representing 6306 total samples. Samples were defined as concurrent if biopsied ≤30 days apart and longitudinal if plasma was coll
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. - 2 day(s) ago
3077 Background: While targeted DNA-seq can detect clinically actionable fusions in tumor tissue samples, technical and analytical challenges may give rise to false negatives. RNA-based, whole-exome sequencing provides a complementary method for fusion detection, and may improve the identification of actionable variants. In this study, we quantify this benefit using a large, real-world clinical dataset to assess actionable fusions detected from RNA in conjunction with DNA profiling. Methods: Using the Tempus Research Database, we retrospectively analyzed a de-identified dataset of ̃80K samples (77.4K patients) profiled with the Tempus xT assay (both DNA-seq with fusion detection in 21 genes and whole exome capture RNA-seq). Only patients that had successful RNA- and DNA-seq were included. Fusions were detected using the Tempus bioinformatic and clinical workflow. Candidate fusions were filtered based on read support thresholds, fusion annotation (i.e., breakpoints, reading frame, conse
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone [Jun 2, 2022] Michuda @benhopark et al. #ASCO22 Abst 3077 https://t.co/eyH5fKlHKu #PrecisionMedicine #lcsm #hpbcsm #btsm #scmsm 1106 fusions classified as targetable by OncoKB https://t.co/kIP8s99gDv
-
-
Mashup Score: 0Yellow fever and malaria control - Lasker Foundation - 2 day(s) ago
Fred L. Soper
Source: laskerfoundation.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7CTG Labs - NCBI - 3 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4CTG Labs - NCBI - 3 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMxByG #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd https://t.co/GQN5ltIS4s
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf
-
Use of the National Cancer Institute Community Cancer Centers Program [NCCCP] Screening and Accrual Log to Address Cancer Clinical Trial Accrual [Jan 14, 2014] St Germain et al. @RonaldGoMD @JCOOP_ASCO https://t.co/Qj10Qi4UM3 #NCORP @theNCI #ClinicalTrials #ctsm https://t.co/5kYZyU5yqq